Companies › VivaVision Biotech
3 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Infectious disease, Ophthalmology, Respiratory; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VVN461 Ophthalmic Solution | – | Phase 3 | Non-infectious Anterior Uveitis | Dec 2026 |
| VVN001 Ophthalmic Solution, 5% | – | Phase 3 | Dry Eye | Apr 2027 |
| VVN432 Nasal Spray | – | Phase 1 | Chronic Rhinosinusitis (CRS) | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07259538 | VVN432 Nasal Spray | Phase 1 | Chronic Rhinosinusitis (CRS) | Respiratory | Nov 2026 |
| NCT07136805 | VVN461 Ophthalmic Solution | Phase 3 | Non-infectious Anterior Uveitis | Infectious disease | Dec 2026 |
| NCT06360133 | VVN001 Ophthalmic Solution, 5% | Phase 3 | Dry Eye | Ophthalmology | Apr 2027 |
No annotated target.
–
Santen SAS Materia Medica Holding Joincare Pharmaceutical Group Industry Alimera Sciences Thirty Respiratory
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.